First US patent granted to Scandion Oncology on combination treatment with its candidate drug SCO-101
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the US Patent and Trademark Office (USPTO) will grant the company’s patent US11,103,481 directed to the use of SCO-101, on August 31, 2021.The granted patent covers combination therapy with Scandion Oncology’s first-in-class lead candidate SCO-101 and is part of the company’s patent family originating from the international application PCT/EP2017/061823. The patent claims the use of SCO-101 in combination with different anti-cancer agents across many cancer indications. The Patent Term for the US patent has been